chartexchange

Prediction: $10,000 Invested in Viking Therapeutics Before Its Oral Phase 3 Readouts Could Be Worth This Much by 2028

The Motley Fool | Nov 13, 2026 4:35 AM EST


Key PointsViking's oral phase 3 obesity trial is key to expanding its addressable market and securing a favorable market share.

Read original article